Reading this on a mobile device? Try our optimized mobile version here:

November 8, 2012
Sign upForwardArchiveAdvertise
News for nuclear medicine and molecular imaging professionals
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items below are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at

  Top Story 
  • Researchers present latest findings from ADNI
    Brain imaging detected amyloid in about 30% of healthy people in their mid-70s without memory problems, according to recent findings from the Alzheimer's Disease Neuroimaging Initiative presented at an Alzheimer's conference. The researchers also found approximately 60% of participants with mild cognitive impairment manifested brain amyloid and 20% to 30% of those patients went on to develop Alzheimer's disease dementia. Prevention trials for people with mild memory problems and for healthy people considered at risk are planned for next year. Medscape (free registration) (11/6) LinkedInFacebookTwitterEmail this Story
"Since we've changed to the Intego system, we've decreased our patient FDG dose by 22%."
—Joseph A. Kmiecik, MD, PhD, Radiologist and RSO at KishHealth System (results based on implementation of weight-based dosing protocol and may vary by site). To hear the full video testimonial about Intego's impact at Kishwaukee Community Hospital, click here.
  Clinical News & Research 
  • PET measures drug response in patients with lung cancer
    Dutch researchers using PET imaging with carbon-11 have discovered that in patients with lung cancer, less than 1% of the drug docetaxel is absorbed by the tumors, and the uptake may be affected by the same-time administration of other drugs. The finding indicates there is a need for the development of better techniques to improve drug targeting for tumors, according to the study, set to be presented at a cancer symposium. More studies are needed to further explore the potential of this imaging method, researchers said. release (11/7) LinkedInFacebookTwitterEmail this Story
  Industry Report 
  • Looking back at innovations that made Cleveland Clinic's list
    Alzheimer's disease molecular imaging agent Amyvid, or florbetapir, was the top innovation on the Cleveland Clinic's list two years ago, and the agent was approved by the FDA this April. Another innovation that has advanced was the top one for 2009: a circulating tumor cell technology. Veridex received FDA approval for its CellSearch System and is developing a subsequent version. (11/6) LinkedInFacebookTwitterEmail this Story
  News from the Field 
  • Medtech industry seeks lame-duck session repeal of device tax
    Industry stakeholders are bracing for post-election efforts to strike down the 2.3% tax set to be levied against medical devices next year. "[W]e will continue to work to highlight what we think are the negatives of the policy for the industry," said J.C. Scott of the Advanced Medical Technology Association, who noted support from House Democrats and incoming Democratic senators for a repeal of the tax. FierceMedicalDevices (11/7) LinkedInFacebookTwitterEmail this Story
  Health Policy 
  • Obama's re-election leads to implementation of ACA in states
    President Barack Obama's victory in this year's presidential election means that the Affordable Care Act must be implemented in every state, regardless of whether governors agree. State officials must inform the federal government on whether and how they plan to run their health insurance exchanges by Nov. 16. Bloomberg (11/7) LinkedInFacebookTwitterEmail this Story
  • Expert: Hamburg's continued role as FDA chief is good for drugmakers
    The pharmaceutical and biotech industry will benefit from the presumed continuation of Dr. Margaret Hamburg as FDA commissioner in President Barack Obama's second term, GlycoMimetics CEO and Biotechnology Industry Organization board member Rachel King said. "The consistency is positive," said King, who points to advances in the latest Prescription Drug User Fee Act, including the new "breakthrough therapies" designation, improved communication between drugmakers and the agency, and the expansion of accelerated approval. American City Business Journals/Washington, D.C. (11/7) LinkedInFacebookTwitterEmail this Story
  Advancing Health Care 
  • NIH launches integrated genetics database
    The NIH's new ClinVar database integrates data from dozens of databases and allows clinical testing laboratories to contribute their data. The database describes diseases using standard nomenclature, allows data to be incorporated into other software and supports complex searches. "It provides a forum that is computer readable for people to develop tools to find connections between genetics and disease," said James Ostell of the NIH's National Center for Biotechnology Information. Nature (11/7) LinkedInFacebookTwitterEmail this Story
  From SNMMI 
  • ACNM/SNMMI and 2nd Sino-American Conference abstract deadline is Nov. 15
    The ACNM and SNMMI are now accepting the submission of original abstracts for the 2013 Mid-Winter Meeting and 2nd Sino-American Conference, Jan. 23-27, 2013, in New Orleans. Young professionals may submit abstracts on the following topics: aspects of clinical and basic science in nuclear medicine, correlative imaging in radiology, nuclear cardiology and radiation oncology. Submission deadline is Nov. 15, 2012. Learn more. LinkedInFacebookTwitterEmail this Story
SNMMI  |  News  |  Meetings  |  Education  |  Publications  |  Membership

SNMMI on Facebook  |  SNMMI on LinkedIn  |  SNMMI on Twitter  |  SNMMI on YouTube

Leave other people's mistakes where they lie."
--Marcus Aurelius,
Roman emperor

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format  | Web version  | Search past news  | Archive  | Privacy policy

Account Director:   Meryl Harold   (202) 407-7828
 Recent SNMMI SmartBrief Issues:   Lead Editor:   Melissa Turner
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.®  Legal Information